25,503 Shares in ChromaDex Co. (NASDAQ:CDXC) Acquired by Millrace Asset Group Inc.

Millrace Asset Group Inc. bought a new stake in ChromaDex Co. (NASDAQ:CDXC) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 25,503 shares of the company’s stock, valued at approximately $93,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. BSW Wealth Partners acquired a new stake in shares of ChromaDex during the 3rd quarter worth $324,000. WINTON GROUP Ltd acquired a new position in shares of ChromaDex in the 2nd quarter valued at about $597,000. SG Americas Securities LLC purchased a new stake in shares of ChromaDex during the 1st quarter worth about $54,000. Marshall Wace LLP acquired a new stake in ChromaDex during the 2nd quarter worth approximately $56,000. Finally, Lazard Asset Management LLC purchased a new position in ChromaDex in the first quarter valued at approximately $43,000. Institutional investors and hedge funds own 15.41% of the company’s stock.

Wall Street Analyst Weigh In

CDXC has been the subject of several research reports. StockNews.com downgraded shares of ChromaDex from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 18th. HC Wainwright upped their price target on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, November 4th. Finally, Roth Mkm raised their price objective on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th.

ChromaDex Stock Up 0.3 %

CDXC opened at $7.46 on Tuesday. The firm’s 50 day moving average is $4.69 and its 200-day moving average is $3.61. ChromaDex Co. has a 52-week low of $1.32 and a 52-week high of $7.85. The firm has a market capitalization of $569.79 million, a P/E ratio of 746.75 and a beta of 1.88.

ChromaDex (NASDAQ:CDXC) last released its quarterly earnings results on Thursday, October 31st. The company reported $0.02 earnings per share (EPS) for the quarter. The firm had revenue of $25.58 million for the quarter, compared to the consensus estimate of $23.70 million. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. During the same quarter in the previous year, the firm posted ($0.01) EPS. Equities analysts expect that ChromaDex Co. will post 0.04 earnings per share for the current fiscal year.

ChromaDex Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.